Health in a Hurry – March 13, 2026

Welcome to another edition of Health in a Hurry, our quick scan of medical news that might otherwise slip under the radar. This week we look at troubling pesticide residues on fruits and vegetables, a new study on blood pressure and brain health, the FDA’s crackdown on telehealth marketing of weight-loss drugs, and a major overhaul of the agency’s adverse event reporting system.

Produce in a Hurry: “Forever” Pesticides on Fruits and Veggies

A new investigation is raising unsettling questions about pesticides on produce. An analysis of California agricultural testing data found that more than a third of samples of conventionally grown fruits and vegetables contained residues of pesticides that qualify as PFAS, also known as “forever chemicals.”

We have been concerned about this collection of chemicals for decades. PFAS stands for per- and polyfluoroalkyl substances. There are many thousands of them. Think nonstick cookware that contained Teflon. These chemicals are also found in food wrappers, waterproof clothing, cosmetics and water.

Now the Environmental Working Group (EWG) reports that PFAS chemicals “contaminate nearly 40% of non-organic California-grown produce.” That means that many of the fruits and vegetables we buy have residues of pesticides containing PFAS compounds: peaches, nectarines, plums, grapes, strawberries, to name just a few of our favorites. Let’s not forget citrus fruits as well.

Scientists call PFAS forever chemicals because they break down extraordinarily slowly in the environment. These compounds accumulate in soil, water and the human body. Research has linked PFAS exposure to liver problems, high cholesterol, immune disruption, fertility problems and certain cancers.

Regulators maintain that approved pesticide uses are safe when applied according to guidelines. Critics counter that safety testing usually evaluates chemicals one at a time. In the real world, however, people may be exposed to a mixture of many such compounds over decades.

Why This Matters

Fruits and vegetables are essential for good health, and we certainly do not want people avoiding produce. But this report highlights a troubling paradox: the foods we rely upon for nutrition may also carry residues of chemicals that persist in the environment for generations. Washing produce under running water is sensible, though it will not necessarily remove all pesticide residues. Organic produce may reduce exposure, but it is often more expensive. The larger question may be whether persistent fluorinated chemicals belong on food crops at all. 

You can learn more about PFAS and How You Can Avoid the Harms from Forever Chemicals at this link.

Blood Pressure in a Hurry: Does Intensive Treatment Harm the Brain?

For years some clinicians have worried that pushing blood pressure too low might reduce blood flow to the brain and accelerate cognitive decline. A new randomized clinical trial from China (Hypertension, Feb. 26, 2026) suggests that concern may be overstated, at least in the short term.

The study, published in the journal Hypertension, followed more than 11,000 adults with hypertension and elevated cardiovascular risk. Participants were assigned to one of two treatment strategies: intensive blood pressure control with a systolic target below 120 mm Hg, or standard treatment targeting a systolic pressure below 140.

After about 3.4 years, researchers found no significant difference in overall cognitive function between the two groups based on Mini-Mental State Examination scores. In other words, lowering systolic blood pressure more aggressively did not appear to harm global cognitive performance during the study period.

This finding may reassure physicians who have worried that intensive treatment could deprive the brain of adequate blood flow. Even among patients with prior stroke or other risk factors for poor cerebral circulation, the study found no evidence that tighter blood pressure control worsened cognitive outcomes.

Why This Matters

The results do not mean that “lower is always better.” Other research suggests that very elderly or frail patients may not tolerate aggressive blood pressure lowering well, especially if it leads to dizziness, falls or very low diastolic pressure. Some studies have even suggested that deprescribing antihypertensive medications in certain nursing home residents may slow cognitive decline. The take-home message is that blood pressure targets should not be one-size-fits-all. For many middle-aged patients, intensive control may be beneficial and cognitively safe. For older, vulnerable patients, clinicians may need to individualize treatment goals carefully.

Telehealth in a Hurry: FDA Targets Online Marketing of GLP-1 Weight-Loss Drugs

Telehealth companies offering weight-loss drugs online are facing increased scrutiny from the FDA. In recent months the agency has issued warning letters to dozens of companies marketing compounded versions of GLP-1 drugs used for obesity treatment.

The concern is that some telehealth sites appeared to imply their products were FDA approved or equivalent to brand-name medications such as Wegovy or Zepbound. Compounded drugs, however, are not evaluated by the FDA for safety and effectiveness in the same way approved medications are.

But the story does not end there. Many of these telehealth companies do not employ their own prescribing physicians. Instead, they rely on a small number of large medical groups that supply clinicians licensed in multiple states. A review of telehealth companies that received FDA warning letters found that a surprisingly large share were connected to just a handful of these “white-label” medical practices operating behind the scenes.

For patients seeking obesity treatment online, the distinction between a telehealth brand and the medical group actually writing the prescriptions may be nearly invisible. Meanwhile, researchers studying the industry found that more than one-third of telehealth sites marketing compounded GLP-1 drugs suggested or implied FDA approval, and many failed to clearly reveal risks or side effects.

Why This Matters

People struggling with weight often feel frustrated and desperate for help. That makes them especially vulnerable to persuasive marketing. Telehealth can expand access to care, but convenience should not come at the expense of transparency. Patients deserve to know whether a medication is FDA approved, compounded by a pharmacy, or being promoted with claims that may overstate its benefits and underplay its risks. Regulators appear increasingly interested in whether the telehealth “supply chain” behind these prescriptions is being adequately monitored.

Drug Safety in a Hurry: FDA Announces New Adverse Drug Reporting System

The FDA has launched a new database designed to track adverse reactions to drugs, vaccines, medical devices and other regulated products. The new platform is called the FDA Adverse Event Monitoring System (AEMS). It replaces a patchwork of older databases that the agency suggests were outdated and difficult to search.

Here at The People’s Pharmacy we have been proponents of FAERS (FDA’s Adverse Event Reporting System). That is because drug companies often miss many serious drug side effects during their initial clinical trial process. Let’s face it, the pharmaceutical industry is motivated to have new medications approved for sale by the FDA.

Detecting side effects is not the main priority. It may take years or even decades for patients to discover serious side effects. Then it can take a long time for the FDA to recognize a problem and change the official prescribing information. You can learn more about Incomplete Drug Side Effect Information at this link.

Previously, the FDA processed roughly six million adverse event reports each year across seven separate systems, including FAERS for drugs and VAERS for vaccines. The new platform will consolidate those reports into a single dashboard that regulators say will make it easier for scientists, researchers and the public to examine potential safety signals.

Eventually the system will include reports involving drugs, biologics, vaccines, medical devices, cosmetics, foods, dietary supplements and tobacco products. The FDA also plans to make adverse event reports available in real time, rather than releasing them quarterly.

However, experts emphasize that the new system will not fix one of the biggest limitations of adverse event reporting: the data themselves. Many adverse reactions are never reported at all. And some FDA officials have confided to us that they don’t trust patient reports about adverse drug reactions.

Why This Matters

Adverse event reporting systems are one of the FDA’s most important tools for detecting safety problems after products reach the market. Clinical trials are rarely large enough to identify delayed side effects. Databases such as FAERS and VAERS can provide early warning signals when clusters of unexpected reactions appear. But these systems are woefully inadequate. A more transparent and user-friendly database could help researchers identify potential problems sooner. Whether it improves drug safety will depend largely on how actively clinicians, patients and manufacturers report adverse reactions. We also need better strategies for disseminating this information so that patients are adequately warned.

Final Words

These short takes are our attempt to highlight important health stories that do not always make the front page. If Health in a Hurry helps you stay informed, or if there are topics you would like us to explore, please let us know. And if you see something you think friends and family would find interesting, please pass this article along. Thank you for supporting our work.